What is the recommended chronic azithromycin regimen for bronchiectasis, including dosing schedule, baseline investigations, monitoring, contraindications, and alternative long‑term therapies?

How to Give Chronic Azithromycin Treatment for Bronchiectasis

For adults with bronchiectasis and ≥3 exacerbations per year, start azithromycin 250 mg three times weekly (Monday-Wednesday-Friday) or 500 mg three times weekly, treating for a minimum of 6 months and up to 12 months. 1

Patient Selection Criteria

Offer chronic azithromycin to patients with:

• Confirmed bronchiectasis on CT scan
• ≥3 exacerbations in the previous 12 months requiring antibiotics 1
• Optimized baseline therapies (airway clearance techniques, pulmonary rehabilitation completed) 1

Dosing Regimens with Strongest Evidence

The three regimens with best supportive data are 1:

• Azithromycin 500 mg three times weekly (Monday-Wednesday-Friday)
• Azithromycin 250 mg daily
• Erythromycin ethylsuccinate 400 mg twice daily

Start with azithromycin 250 mg three times weekly to minimize side effects, then titrate up to 500 mg three times weekly based on clinical response if needed. 1 The most recent ERS guideline also supports 250 mg daily or 500 mg three times weekly 2.

Mandatory Baseline Investigations

Before starting azithromycin, obtain 1:

Cardiac screening:

• Baseline ECG to measure QTc interval
• Do NOT start if QTc >450 ms (men) or >470 ms (women) - this is an absolute contraindication
• Review all medications for QT-prolonging drugs (antiarrhythmics, antipsychotics, fluoroquinolones, methadone, some antimalarials/antiretrovirals) 1

Microbiological screening:

• Sputum culture including specific testing for nontuberculous mycobacteria (NTM)
• Avoid macrolide monotherapy if NTM is identified - this will induce resistance 1
• Stop azithromycin for 2 weeks before NTM testing to avoid false negatives 1

Laboratory tests:

• Baseline liver function tests 1

Clinical assessment:

• Accurate baseline exacerbation rate over previous 12 months 1

Monitoring During Treatment

At 1 month after starting 1:

• Repeat ECG - stop immediately if QTc becomes prolonged (>450 ms men, >470 ms women)
• Liver function tests
• Assess for side effects (GI upset, hearing/balance problems)

Every 6 months 1:

• Liver function tests
• Sputum culture if able to expectorate (monitor for resistance patterns)
• Medication review for new QT-prolonging drugs

At 6 and 12 months 1:

• Assess efficacy using objective measures:
  • Exacerbation frequency compared to baseline
  • Quality of life scores
  • Symptom burden
• Stop treatment if no benefit is demonstrated

Treatment Duration

• Minimum duration: 6 months to assess impact 1
• Optimal assessment period: up to 12 months 1
• Evidence beyond 12 months is limited 2, 1

After 12 months of benefit: Consider discontinuation or a treatment break (e.g., 3-6 months during summer months) to reduce resistance development while maintaining efficacy 1. The most recent ERS guideline suggests discontinuation may be considered after 1 year if remission is achieved, though relapse risk must be discussed 2.

Contraindications

Absolute contraindications:

• QTc >450 ms (men) or >470 ms (women) 1
• Concurrent use of other QT-prolonging medications 1
• Active NTM infection (relative - requires multi-drug NTM regimen, not monotherapy) 1

Common Side Effects and Management

Gastrointestinal effects (most common) 1:

• Diarrhea and abdominal pain occur in ~40% of patients
• If GI side effects occur on 500 mg three times weekly, reduce to 250 mg three times weekly if clinical benefit has been demonstrated 1
• Rarely requires discontinuation

Other adverse effects to counsel patients about 1:

• Hearing and balance disturbance
• Cardiac effects (QTc prolongation)
• Development of antimicrobial resistance (occurs in ~88% vs 26% placebo) 3

Expected Benefits

Based on the landmark BAT trial 3:

• Median exacerbations reduced from 2 to 0 over 12 months
• 80% of placebo patients had ≥1 exacerbation vs 46% on azithromycin
• Modest improvement in FEV1 (increase of 1.03% per 3 months vs decrease of 0.10% in placebo)
• May reduce sputum volume 1

Alternative Long-Term Therapies

Long-term non-macrolide oral antibiotics are NOT recommended as first-line treatment 2. They may have a role only when macrolides are contraindicated or ineffective, but evidence is very low quality with unfavorable risk-benefit profile 2.

Consider inhaled antibiotics or other therapies if azithromycin fails or is contraindicated, though this requires specialist respiratory consultation.

Critical Pitfalls to Avoid

• Never start without baseline ECG - sudden cardiac death risk with undetected QTc prolongation
• Never start without NTM screening - macrolide monotherapy induces NTM resistance
• Never continue beyond 12 months without documented benefit - resistance concerns outweigh benefits
• Never ignore new QTc prolongation at 1-month follow-up - requires immediate discontinuation
• Do not stop azithromycin during acute exacerbations unless another QT-prolonging antibiotic is prescribed 1